Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial

BACKGROUND: MeRes100™ (Meril Life Sciences Pvt. Ltd., Vapi, India) is a novel sirolimus-eluting bioresorbable vascular scaffold (BRS). The purpose of this sub-study of MeRes-1 trial is to evaluate the systemic release of sirolimus from MeRes100 BRS implanted for the treatment of de novo native coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandra, Praveen, Mahajan, Ajaykumar U., Bulani, Vipin D., Thakkar, Ashok S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306117/
https://www.ncbi.nlm.nih.gov/pubmed/30627287
http://dx.doi.org/10.14740/cr799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306117/
https://www.ncbi.nlm.nih.gov/pubmed/30627287
http://dx.doi.org/10.14740/cr799

Ejemplares similares